Literature DB >> 9657765

The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells.

L Cragg1, R P Hebbel, W Miller, A Solovey, S Selby, H Enright.   

Abstract

Iron-mediated carcinogenesis is thought to occur through the generation of oxygen radicals. Iron chelators are used in attempts to prevent the long term consequences of iron overload. In particular, 1,2-dimethyl-3-hydroxypyrid-4-one (L1), has shown promise as an effective chelator. Using an established hepatocellular model of iron overload, we studied the generation of iron-catalyzed oxidative DNA damage and the influence of iron chelators, including L1, on such damage. Iron loading of HepG2 cells was found to greatly exacerbate hydrogen peroxide-mediated DNA damage. Desferrithiocin was protective against iron/hydrogen peroxide-induced DNA damage; deferoxamine had no effect. In contrast, L1 exposure markedly potentiated hydrogen peroxide-mediated oxidative DNA damage in iron-loaded liver cells. However, when exposure to L1 was maintained during incubation with hydrogen peroxide, L1 exerted a protective effect. We interpret this as indicating that L1's potential toxicity is highly dependent on the L1:iron ratio. In vitro studies examining iron-mediated ascorbate oxidation in the presence of L1 showed that an L1:iron ratio must be at least 3 to 1 for L1 to inhibit the generation of free radicals; at lower concentrations of L1 increased oxygen radical generation occurs. In the clinical setting, such potentiation of iron-catalyzed oxidative DNA damage at low L1:iron ratios may lead to long-term toxicities that might preclude administration of L1 as an iron chelator. Whether this implication in fact extends to the in vivo situation will have to be verified in animal studies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657765

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Desferrithiocin is a more potent antineoplastic agent than desferrioxamine.

Authors:  Anthony Kicic; Anita C G Chua; Erica Baker
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation.

Authors:  Jolyn Turner; Constantinos Koumenis; Timothy E Kute; Roy P Planalp; Martin W Brechbiel; Dillon Beardsley; Brooke Cody; Kevin D Brown; Frank M Torti; Suzy V Torti
Journal:  Blood       Date:  2005-07-12       Impact factor: 22.113

Review 3.  Preconditioning against renal ischaemia reperfusion injury: the failure to translate to the clinic.

Authors:  Dermot O'Kane; Graham S Baldwin; Damien M Bolton; Joseph J Ischia; Oneel Patel
Journal:  J Nephrol       Date:  2019-01-11       Impact factor: 3.902

4.  Studies on the redox activity of iron N,O-complexes: Potential T1-contrast agents.

Authors:  Nikodem Kuźnik; Urszula Chmielniak
Journal:  Redox Rep       Date:  2016-02-18       Impact factor: 4.412

5.  Prevention of acetic acid-induced colitis by desferrithiocin analogs in a rat model.

Authors:  Raymond J Bergeron; Jan Wiegand; William R Weimar; John Nhut Nguyen; Charles A Sninsky
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

Review 6.  Iron chelation and multiple sclerosis.

Authors:  Kelsey J Weigel; Sharon G Lynch; Steven M LeVine
Journal:  ASN Neuro       Date:  2014-01-30       Impact factor: 4.146

Review 7.  Altered Iron Metabolism and Impact in Cancer Biology, Metastasis, and Immunology.

Authors:  Rikki A M Brown; Kirsty L Richardson; Tasnuva D Kabir; Debbie Trinder; Ruth Ganss; Peter J Leedman
Journal:  Front Oncol       Date:  2020-04-09       Impact factor: 6.244

Review 8.  Iron: An Essential Element of Cancer Metabolism.

Authors:  Myriam Y Hsu; Erica Mina; Antonella Roetto; Paolo E Porporato
Journal:  Cells       Date:  2020-12-03       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.